Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript
Cytosorbents Corporation ( CTSO ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Phillip Chan - CEO & Director Peter Mariani - Chief Financial Officer Conference Call Participants Adanna Alexander Brian Lantier - Zacks Small-Cap Research Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents Corp. Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 13 of 2025.
Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Peter J. Mariani - Chief Financial Officer Phillip P.
Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Phillip Chan - Chief Executive Officer Makis Deliargyris - Chief Medical Officer Pete Mariani - Chief Financial Officer Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H.C. Wainwright Michael Kim - Zacks Small-Capital Research Operator Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents First Quarter 2025 Earnings Conference Call.
Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Adanna Alexander – IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H. C. Wainwright Thomas Kerr - Zacks Small Cap Research Operator Good afternoon, ladies and gentleman and welcome to the CytoSorbents' Corporation Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlight Conference Call.
Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Tom Kerr - Zacks Small-Cap Research Operator Thank you for standing by. My name is Catherine, and I will be your conference operator today.
Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Eric Ribner - IR Phillip Chan - CEO Kathleen Bloch - CFO Vincent Capponi - President & COO Makis Deliargyris - Chief Medical Officer Peter Mariani - CFO Conference Call Participants Michael Sarcone - Jefferies Yuan Zhi - B. Riley Securities Tom Kerr - Zacks Investment Research Sean Lee - H.C.
B. Riley Weighs in on Cytosorbents Co.’s Q2 2024 Earnings (NASDAQ:CTSO)
Cytosorbents Co. (NASDAQ:CTSO – Free Report) – Equities research analysts at B. Riley dropped their Q2 2024 earnings per share estimates for Cytosorbents in a research note issued on Wednesday, May 15th. B. Riley analyst Y. Zhi now forecasts that the medical research company will post earnings per share of ($0.09) for the quarter, down from their previous forecast of ($0.07). B. Riley currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.35) per share. B. Riley also issued estimates for Cytosorbents’ Q3 2024 earnings at ($0.08) EPS, Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.34) EPS and FY2025 earnings at ($0.28) EPS. Cytosorbents (NASDAQ:CTSO – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. The firm had revenue of $9.79 million for the quarter, compared to the consensus estimate of $9.78 million. During the same quarter last year, the business posted ($0.17) earnings per share. CTSO has been the subject of a number of other reports. StockNews.com initiated coverage on Cytosorbents in a report on Saturday. They set a “hold” rating for the company. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Tuesday, May 7th. Get Our Latest Research Report on CTSO Cytosorbents Stock Performance Shares of Cytosorbents stock opened at $0.97 on Monday. Cytosorbents has a one year low of $0.78 and a one year high of $4.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.21 and a current ratio of 1.49. The company has a market cap of $52.55 million, a price-to-earnings ratio of -1.64 and a beta of 0.62. The business’s 50 day moving average price is $0.89 and its 200 day moving average price is $1.07. Institutional Trading of Cytosorbents Several hedge funds have recently made changes to their positions in the business. Key Client Fiduciary Advisors LLC boosted its stake in shares of Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after buying an additional 22,557 shares during the period. Raymond James & Associates purchased a new position in Cytosorbents in the fourth quarter worth approximately $56,000. Sargent Investment Group LLC lifted its stake in Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after acquiring an additional 51,699 shares during the last quarter. Avenir Corp lifted its stake in Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after acquiring an additional 121,294 shares during the last quarter. Finally, Neuberger Berman Group LLC lifted its stake in Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock. About Cytosorbents (Get Free Report) Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
